Short answer: the schedule exists to protect your stomach, not to ration the effect
The label gives the reason for the climb in one sentence: "Follow the dosage escalation below for all indications to reduce the risk of gastrointestinal adverse reactions." That is the answer to why anyone starts at 2.5 mg and moves up rather than beginning at an effective dose. The starting dose is not a weak version of the treatment, it is an on-ramp, and the label rules it out as a destination: "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." Whether you personally move up a step is a separate question, and it belongs to your prescriber. What this page can give you is the published trade-off they are weighing, with the gain and the cost of each strength side by side.
The schedule, in the label's own terms
Section 2.1 is short. The starting dosage is 2.5 mg once weekly for 4 weeks. After 4 weeks the dosage increases to 5 mg once weekly. From there it "may be increased in 2.5 mg increments, after at least 4 weeks on the current dose", up to a maximum of 15 mg once weekly.
Two details in that paragraph get lost in the usual retelling. The interval is a floor, not a timetable: "after at least 4 weeks" permits waiting longer and does not require moving at four. And the ladder has six rungs while the list of recommended maintenance dosages has three, 5 mg, 10 mg and 15 mg, which is why 7.5 mg and 12.5 mg behave like steps rather than destinations. That distinction is worked through in the Zepbound maintenance dose guide.
What a step up buys, and what it costs
Nearly every page on this question lists reasons to increase and stops there. The same documents quantify the other side of it. The weight figures below are from SURMOUNT-1, a 72 week trial of 2,539 adults randomised to a target dose; the adverse reaction figures are from the pooled safety analysis of two weight reduction trials in the label.
| Weekly dose | Mean weight change at 72 weeks | Severe gastrointestinal adverse reactions | Stopped treatment because of an adverse reaction |
|---|---|---|---|
| Placebo | 3.1% lost | 1.0% | 3.4% |
| 5 mg | 15.0% lost | 1.7% | 4.8% |
| 10 mg | 19.5% lost | 2.5% | 6.3% |
| 15 mg | 20.9% lost | 3.1% | 6.7% |
Read the shape of it rather than the individual numbers. The jump from 5 mg to 10 mg is worth about 4.5 percentage points of body weight on average; the jump from 10 mg to 15 mg is worth about 1.4. The cost column rises steadily across the whole range. That is the trade-off section 2.1 is pointing at when it says to "consider treatment response and tolerability when selecting the maintenance dosage".
The caveat that keeps this table honest
SURMOUNT-1 randomised people to a target dose at the start and escalated them to it over 20 weeks. It did not test the decision this page is about, which is whether an individual already on a dose should move up. So these are group averages over 72 weeks, not a prediction of what one extra step will do for one person, and the label's own warning applies: adverse reaction rates from a clinical trial "may not reflect the rates observed in practice".
Why the first weeks feel strongest, and why that is not a reason by itself
A large share of the people searching this question are not asking about pharmacology. They are asking why something that worked at the start seems to have faded. The label has a sentence that speaks directly to it, in section 12.2: "Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time."
So part of what changes over the first weeks is expected and is described in the document. Fullness driven by slower stomach emptying is at its most pronounced early and settles, while the drug's concentration in your blood is doing the opposite, rising to steady state after about 4 weeks of weekly dosing. Those two curves moving in opposite directions is what "it stopped working" often turns out to be. Whether that means a dose change, more time at the current dose, or something else entirely is exactly the judgement the label hands to your prescriber.
What the label actually hands the prescriber
- Response and tolerability together. "Consider treatment response and tolerability when selecting the maintenance dosage."
- Explicit permission to go down. "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." Escalation is not a one way ratchet in the document.
- A minimum time at each step. Increases come "after at least 4 weeks on the current dose", which is also roughly when concentrations reach steady state.
- A ceiling. "The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly."
One more number is worth carrying into that conversation: in the pooled trials, "the majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions". The early period is where tolerability decides whether treatment continues at all, which is the whole reason the ramp exists. If side effects are the live issue, the three levers the label names for reducing them covers what the document actually supports.
The record that makes the decision quick
A dose conversation goes faster when three things are facts rather than impressions: how many weeks you have been at the current strength, what the weight trend has done over those weeks, and which side effects happened on which day relative to the injection. The last one matters more than it sounds, because a symptom that reliably lands two days after every injection reads very differently from one that does not. Logging doses and symptoms against the date, which is what a GLP-1 tracking app is for, turns all three into something you can show.
Frequently asked questions
Do I have to increase my Zepbound dose?
The label requires the first move, from the 2.5 mg initiation dose, because 2.5 mg is not an approved maintenance dosage. Above that it says increases "may" be made and that the maintenance dosage is selected on response and tolerability. That is a prescriber decision and the document does not compel a particular destination.
Why do I have to start at 2.5 mg at all?
To reduce the risk of gastrointestinal adverse reactions. That is the stated purpose of the escalation schedule in section 2.1, and the discontinuation data shows why: most people who stopped because of side effects did so in the first few months, and those side effects were gastrointestinal.
Will a higher dose work faster?
The trial data compares final weight change at 72 weeks, not speed, and SURMOUNT-1 escalated participants to their target dose over 20 weeks. There is no published figure for how much faster a higher dose acts. Concentrations reach steady state about 4 weeks after any change in weekly dose.
Can I go back down if a higher dose does not suit me?
The label addresses this directly: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." Any change is made by your prescriber.
Is 7.5 mg a dose I can stay on?
It is an available strength and an escalation step, but section 2.2 lists only 5 mg, 10 mg and 15 mg as recommended maintenance dosages. Staying on it is a prescriber judgement rather than a labelled option.
Side effects came back after my last increase. Is that expected?
Gastrointestinal reactions were most common during dose escalation in the trials, which is the pattern the schedule is designed to blunt. Expected is not the same as acceptable, and severe or persistent symptoms are a reason to contact your prescriber rather than to wait it out. See when Zepbound side effects start for the timing the label and trials actually report.
Related reading
- Zepbound maintenance dose after goal weight, the three dosages the label names and the two it does not
- How long does Zepbound take to work?, the three clocks behind "it stopped working"
- How do you reduce the side effects of Zepbound?, the three levers in the label
- Do Zepbound side effects start right away?, what the label can and cannot tell you about timing
- Best GLP-1 app, for logging doses and symptoms against the date
Sources
- ZEPBOUND (tirzepatide) US prescribing information, Eli Lilly and Company. Section 2.1 for the escalation schedule and its stated purpose, section 2.2 for maintenance and maximum dosages, section 5.2 for severe gastrointestinal adverse reaction rates by dose, section 6.1 for discontinuation rates and their timing, section 12.2 for gastric emptying and section 12.3 for steady state.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024. Trial registration NCT04184622. Source of the 72 week weight figures and the 20 week dose-escalation period.
- ZEPBOUND label on DailyMed, US National Library of Medicine, for an independently hosted copy of the same label.
This page summarises published prescribing information and trial results for general education. It is not medical advice, it is not a recommendation to change your dose, and it contains no dosing instruction. Dose escalation decisions belong to your prescriber. Contact them about side effects rather than adjusting treatment yourself.
Jabby is free on the App Store and lines side effects up against the dose and the day they happened, which is the evidence a dose conversation turns on.